{"id":"daratumumab-plus-velcade-cyclophosphamide-dexamethasone","safety":{"commonSideEffects":[{"rate":"20-50%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"5-20%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL1743007","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Daratumumab works by binding to CD38 on the surface of multiple myeloma cells, marking them for destruction by the immune system. Velcade blocks the action of proteasomes, which are responsible for breaking down proteins in cells, leading to cell death. Cyclophosphamide and Dexamethasone are chemotherapy drugs that kill cancer cells by interfering with their DNA and cell division.","oneSentence":"Daratumumab is a monoclonal antibody that targets CD38, a protein found on the surface of multiple myeloma cells, while Velcade is a proteasome inhibitor that blocks the action of proteasomes, which are responsible for breaking down proteins in cells, and Cyclophosphamide and Dexamethasone are chemotherapy drugs that kill cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:31:08.191Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of multiple myeloma"}]},"trialDetails":[{"nctId":"NCT06413498","phase":"PHASE3","title":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2024-08-23","conditions":"Multiple Myeloma","enrollment":450},{"nctId":"NCT05257083","phase":"PHASE3","title":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2023-10-10","conditions":"Multiple Myeloma","enrollment":759},{"nctId":"NCT04181827","phase":"PHASE3","title":"A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2020-06-12","conditions":"Multiple Myeloma","enrollment":419},{"nctId":"NCT06577025","phase":"PHASE2","title":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-08-20","conditions":"Multiple Myeloma","enrollment":43},{"nctId":"NCT07149857","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-10-03","conditions":"Multiple Myeloma","enrollment":60},{"nctId":"NCT06142396","phase":"EARLY_PHASE1","title":"Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure","status":"RECRUITING","sponsor":"Augusta University","startDate":"2024-11-01","conditions":"Multiple Myeloma, Renal Failure","enrollment":30},{"nctId":"NCT06627309","phase":"","title":"Rapid dFLC Response Predict CHR in AL Amyloidosis","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-10-26","conditions":"Systemic AL Amyloidosis","enrollment":50},{"nctId":"NCT06083922","phase":"PHASE2","title":"A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-10-16","conditions":"Multiple Myeloma, Monoclonal Gammopathy of Renal Significance","enrollment":20},{"nctId":"NCT04656951","phase":"PHASE2","title":"Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cologne","startDate":"2021-06-01","conditions":"Multiple Myeloma","enrollment":67},{"nctId":"NCT05250973","phase":"PHASE2","title":"A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-03-01","conditions":"Amyloidosis","enrollment":151},{"nctId":"NCT07341867","phase":"PHASE1","title":"Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype","status":"NOT_YET_RECRUITING","sponsor":"Andrew Hantel, MD","startDate":"2026-06","conditions":"Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation","enrollment":90},{"nctId":"NCT04991103","phase":"PHASE2","title":"Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2021-09-22","conditions":"Multiple Myeloma, Amyloidosis","enrollment":40},{"nctId":"NCT07072585","phase":"PHASE2, PHASE3","title":"Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)","status":"NOT_YET_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2026-06-28","conditions":"Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma","enrollment":1708},{"nctId":"NCT04973137","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis","status":"TERMINATED","sponsor":"Prothena Biosciences Ltd.","startDate":"2021-08-30","conditions":"Light Chain (AL) Amyloidosis","enrollment":208},{"nctId":"NCT03201965","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-10-05","conditions":"Amyloidosis","enrollment":416},{"nctId":"NCT06022939","phase":"PHASE3","title":"Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis","status":"RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2024-07-01","conditions":"AL Amyloidosis","enrollment":338},{"nctId":"NCT03004287","phase":"PHASE2","title":"2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arkansas","startDate":"2017-07-01","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT01415882","phase":"PHASE2","title":"Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2012-01-31","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":165},{"nctId":"NCT07085728","phase":"PHASE2","title":"Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure","status":"NOT_YET_RECRUITING","sponsor":"Eastern Cooperative Oncology Group","startDate":"2025-08-11","conditions":"Myeloma Multiple","enrollment":74},{"nctId":"NCT03896737","phase":"PHASE2","title":"Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2019-04-16","conditions":"Multiple Myeloma","enrollment":401},{"nctId":"NCT04166565","phase":"PHASE2","title":"Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2019-10-31","conditions":"Multiple Myeloma, Extramedullary Plasmacytoma","enrollment":41},{"nctId":"NCT04304144","phase":"PHASE2","title":"A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2020-03-18","conditions":"AL Amyloidosis","enrollment":25},{"nctId":"NCT06771180","phase":"PHASE2","title":"Dara-BCD for Rare MGRS","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-01-15","conditions":"Monoclonal Gammopathy of Renal Significance (MGRS)","enrollment":10},{"nctId":"NCT06418477","phase":"PHASE2","title":"Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-06-15","conditions":"Monoclonal Gammopathy of Renal Significance","enrollment":20},{"nctId":"NCT03188172","phase":"PHASE2","title":"MUK Nine b: OPTIMUM Treatment Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Leeds","startDate":"2017-09-28","conditions":"Multiple Myeloma","enrollment":95},{"nctId":"NCT02513186","phase":"PHASE1","title":"Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-09-30","conditions":"Plasma Cell Myeloma","enrollment":90},{"nctId":"NCT02951819","phase":"PHASE2","title":"A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2016-11-09","conditions":"Multiple Myeloma","enrollment":101},{"nctId":"NCT04065308","phase":"PHASE2","title":"Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2019-01-14","conditions":"Multiple Myeloma in Relapse, Plasmacytoma, Daratumumab","enrollment":33},{"nctId":"NCT02955810","phase":"PHASE1","title":"Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)","status":"UNKNOWN","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2016-11","conditions":"Multiple Myeloma","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Daratumumab plus Velcade Cyclophosphamide Dexamethasone","genericName":"Daratumumab plus Velcade Cyclophosphamide Dexamethasone","companyName":"Stichting European Myeloma Network","companyId":"stichting-european-myeloma-network","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Daratumumab is a monoclonal antibody that targets CD38, a protein found on the surface of multiple myeloma cells, while Velcade is a proteasome inhibitor that blocks the action of proteasomes, which are responsible for breaking down proteins in cells, and Cyclophosphamide and Dexamethasone are chemotherapy drugs that kill cancer cells. Used for Treatment of multiple myeloma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}